IPO Databook: Alzamend Neuro (ALZN US) - Aug 2026

91 Views23 Aug 2026 10:11

SUMMARY

Alzamend Neuro, Inc. develops novel therapeutics for Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. This prospectus registers shares for resale.
AL001 Phase IIA clinical trial completed March 2023 with positive topline data announced June 2023. ALZN002 initiated Phase I/IIA clinical trial April 2023.
The auditor's report includes an explanatory paragraph regarding the company’s ability to continue as a going concern, with significant losses since inception.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream